{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T12:23:56Z","timestamp":1789820636971,"version":"4.0.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T00:00:00Z","timestamp":1350345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Aminobisphosphonates (NBPs) are used widely against excessive bone resorption in osteoporosis and Paget's disease as well as in metastatic bone disease and multiple myeloma. Intravenous NBP administration often causes mild to severe acute-phase responses (APRs) that may require intervention with analgesics and antipyretics and lead to treatment noncompliance and nonadherence. We here undertook a phase IV safety trial in patients with osteoporosis to investigate the APR of otherwise healthy individuals to first-time intravenous treatment with the NBP zoledronate. This study provides unique insight into sterile acute inflammatory responses in vivo, in the absence of confounding factors such as infection or cancer. Our data show that both peripheral \u03b3\u03b4 T cells and monocytes become rapidly activated after treatment with zoledronate, which ultimately determines the clinical severity of the APR. Our study highlights a key role for IFN-\u03b3 in the zoledronate-induced APR and identifies pretreatment levels of monocytes and central\/memory V\u03b39\/V\u03b42 T cells as well as their responsiveness to zoledronate in vitro as predictive risk factors for the occurrence of subclinical and clinical symptoms. These findings have diagnostic and prognostic implications for patients with and without malignancy and are relevant for V\u03b39\/V\u03b42 T-cell\u2013based immunotherapy approaches. \u00a9 2012 American Society for Bone and Mineral Research. \u00a9 2013 American Society for Bone and Mineral Research.<\/jats:p>","DOI":"10.1002\/jbmr.1797","type":"journal-article","created":{"date-parts":[[2012,10,16]],"date-time":"2012-10-16T09:36:18Z","timestamp":1350380178000},"page":"464-471","source":"Crossref","is-referenced-by-count":63,"title":["Monocytes and \u03b3\u03b4 T cells control the acute-phase response to intravenous zoledronate: Insights from a phase IV safety trial"],"prefix":"10.1093","volume":"28","author":[{"given":"Joanne L","family":"Welton","sequence":"first","affiliation":[{"name":"Cardiff Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt P","family":"Morgan","sequence":"additional","affiliation":[{"name":"Cardiff Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador","family":"Mart\u00ed","sequence":"additional","affiliation":[{"name":"Cardiff Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Stone","sequence":"additional","affiliation":[{"name":"Bone Research Unit, Cardiff University Academic Centre, Llandough Hospital, Penarth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Moser","sequence":"additional","affiliation":[{"name":"Cardiff Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew K","family":"Sewell","sequence":"additional","affiliation":[{"name":"Cardiff Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Turton","sequence":"additional","affiliation":[{"name":"Bone Research Unit, Cardiff University Academic Centre, Llandough Hospital, Penarth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eberl","sequence":"additional","affiliation":[{"name":"Cardiff Institute of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,10,16]]},"reference":[{"key":"2024020318425778100_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2781","article-title":"\u03b3\u03b4 T cell effector functions: a blend of innate programming and acquired plasticity","volume":"10","author":"Bonneville","year":"2010","journal-title":"Nat Rev Immunol."},{"key":"2024020318425778100_bib2","doi-asserted-by":"crossref","first-page":"e1000308","DOI":"10.1371\/journal.ppat.1000308","article-title":"A rapid crosstalk of human \u03b3\u03b4 T cells and monocytes drives the acute inflammation in bacterial infections","volume":"5","author":"Eberl","year":"2009","journal-title":"PLoS Pathog."},{"key":"2024020318425778100_bib3","doi-asserted-by":"crossref","first-page":"e1002040","DOI":"10.1371\/journal.ppat.1002040","article-title":"Human neutrophil clearance of bacterial pathogens triggers anti-microbial \u03b3\u03b4 T cell responses in early infection","volume":"7","author":"Davey","year":"2011","journal-title":"PLoS Pathog."},{"key":"2024020318425778100_bib4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.it.2009.09.001","article-title":"Monocytes and \u03b3\u03b4 T cells: close encounters in microbial infection","volume":"30","author":"Eberl","year":"2009","journal-title":"Trends Immunol."},{"key":"2024020318425778100_bib5","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1007\/s00018-011-0706-6","article-title":"\u03b3\u03b4 T-APCs: a novel tool for immunotherapy?","volume":"68","author":"Moser","year":"2011","journal-title":"Cell Mol Life Sci."},{"key":"2024020318425778100_bib6","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","article-title":"Management of the adverse effects associated with intravenous bisphosphonates","volume":"17","author":"Tanvetyanon","year":"2006","journal-title":"Ann Oncol."},{"key":"2024020318425778100_bib7","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporosis Int."},{"key":"2024020318425778100_bib8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s002239900353","article-title":"An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates","volume":"61","author":"Thi\u00e9baud","year":"1997","journal-title":"Calcif Tissue Int."},{"key":"2024020318425778100_bib9","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.57.9.572","article-title":"Evaluation of adverse experiences related to pamidronate infusion in Paget's disease of bone","volume":"57","author":"Buckler","year":"1998","journal-title":"Ann Rheum Dis."},{"issue":"11","key":"2024020318425778100_bib10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/107999003322558782","article-title":"Fever after zoledronic acid administration is due to increase in TNF-\u03b1 and IL-6","volume":"23","author":"Dicuonzo","year":"2003","journal-title":"J Interferon Cytokine Res."},{"key":"2024020318425778100_bib11","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1210\/jc.2010-0597","article-title":"Characterization of and risk factors for the acute-phase response after zoledronic acid","volume":"95","author":"Reid","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"key":"2024020318425778100_bib12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med."},{"key":"2024020318425778100_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJM199903043400914","article-title":"\u03b3\/\u03b4 T-cell stimulation by pamidronate","volume":"340","author":"Kunzmann","year":"1999","journal-title":"N Engl J Med."},{"key":"2024020318425778100_bib14","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood.V96.2.384.013k07_384_392","article-title":"Stimulation of \u03b3\u03b4 T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma","volume":"96","author":"Kunzmann","year":"2000","journal-title":"Blood."},{"key":"2024020318425778100_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1084\/jem.20021500","article-title":"Human T cell receptor \u03b3\u03b4 cells recognize endogenous mevalonate metabolites in tumor cells","volume":"197","author":"Gober","year":"2003","journal-title":"J Exp Med."},{"key":"2024020318425778100_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood \u03b3\u03b4 T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin Exp Immunol."},{"key":"2024020318425778100_bib17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2008.07435.x","article-title":"Peripheral blood monocytes are responsible for \u03b3\u03b4 T cell activation induced by zoledronic acid through accumulation of IPP\/DMAPP","volume":"144","author":"Roelofs","year":"2009","journal-title":"Br J Haematol."},{"key":"2024020318425778100_bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.bone.2010.10.177","article-title":"Fluvastatin does not prevent the acute-phase response to intravenous zoledronic acid in post-menopausal women","volume":"49","author":"Thompson","year":"2011","journal-title":"Bone."},{"key":"2024020318425778100_bib19","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1002\/eji.201242492","article-title":"Human \u03b3\u03b4 T-cell responses in infection and immunotherapy: common mechanisms, common mediators?","volume":"42","author":"Riganti","year":"2012","journal-title":"Eur J Immunol."},{"key":"2024020318425778100_bib20","first-page":"18","article-title":"Can peripheral blood \u03b3\u03b4 T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug-effects of aminobisphosphonate therapy","author":"Kalyan","year":"2012","journal-title":"J Bone Miner Res."},{"key":"2024020318425778100_bib21","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.4049\/jimmunol.166.9.5508","article-title":"Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human \u03b3\u03b4 T cells by aminobisphosphonate antigen","volume":"166","author":"Miyagawa","year":"2001","journal-title":"J Immunol."},{"key":"2024020318425778100_bib22","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00198-010-1448-2","article-title":"Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid","volume":"22","author":"Silverman","year":"2011","journal-title":"Osteoporos Int."},{"key":"2024020318425778100_bib23","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1182\/blood-2009-07-234211","article-title":"Human \u03b3\u03b4 T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement","volume":"116","author":"Maniar","year":"2010","journal-title":"Blood."},{"key":"2024020318425778100_bib24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/jbmr.521","article-title":"Circulating \u03b3\u03b4 T cells and the risk of acute-phase response after zoledronic acid administration","volume":"27","author":"Rossini","year":"2012","journal-title":"J Bone Miner Res."},{"key":"2024020318425778100_bib25","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1189\/jlb.1105640","article-title":"Sex-specific phenotypical and functional differences in peripheral human V\u03b39\/V\u03b42 T cells","volume":"79","author":"Caccamo","year":"2006","journal-title":"J Leukoc Biol."},{"key":"2024020318425778100_bib26","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2003-05-1655","article-title":"Induction of \u03b3\u03b4 T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo","volume":"102","author":"Dieli","year":"2003","journal-title":"Blood."},{"key":"2024020318425778100_bib27","doi-asserted-by":"crossref","first-page":"7450","DOI":"10.1158\/0008-5472.CAN-07-0199","article-title":"Targeting human \u03b3\u03b4 T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer","volume":"67","author":"Dieli","year":"2007","journal-title":"Cancer Res."},{"key":"2024020318425778100_bib28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","article-title":"In vivo manipulation of V\u03b39V\u03b42 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients","volume":"161","author":"Meraviglia","year":"2010","journal-title":"Clin Exp Immunol."},{"key":"2024020318425778100_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-008-0521-6","article-title":"In vivo effects of zoledronic acid on peripheral \u03b3\u03b4 T lymphocytes in early breast cancer patients","volume":"58","author":"Santini","year":"2009","journal-title":"Cancer Immunol Immunother."},{"key":"2024020318425778100_bib30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1084\/jem.20030235","article-title":"Differentiation of effector\/memory V\u03b42 T cells and migratory routes in lymph nodes or inflammatory sites","volume":"198","author":"Dieli","year":"2003","journal-title":"J Exp Med."},{"key":"2024020318425778100_bib31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1359\/jbmr.081016","article-title":"Atorvastatin may have no effect on acute phase reaction in children after intravenous bisphosphonate infusion","volume":"24","author":"Srivastava","year":"2009","journal-title":"J Bone Miner Res."},{"key":"2024020318425778100_bib32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00223-011-9468-2","article-title":"No effect of rosuvastatin in the zoledronate-induced acute-phase response","volume":"88","author":"Makras","year":"2011","journal-title":"Calcif Tissue Int."},{"key":"2024020318425778100_bib33","doi-asserted-by":"crossref","first-page":"5471","DOI":"10.4049\/jimmunol.175.8.5471","article-title":"In vivo immunomanipulation of V\u03b39V\u03b42 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model","volume":"175","author":"Sicard","year":"2005","journal-title":"J Immunol."},{"key":"2024020318425778100_bib34","doi-asserted-by":"crossref","first-page":"8287","DOI":"10.4049\/jimmunol.179.12.8287","article-title":"Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic V\u03b32V\u03b42 T cells in macaques","volume":"179","author":"Ali","year":"2007","journal-title":"J Immunol."},{"key":"2024020318425778100_bib35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1359\/jbmr.090704","article-title":"Potential mediators of the mortality reduction with zoledronic acid after hip fracture","volume":"25","author":"Col\u00f3n-Emeric","year":"2010","journal-title":"J Bone Miner Res."},{"key":"2024020318425778100_bib36","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol."},{"key":"2024020318425778100_bib37","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet."},{"key":"2024020318425778100_bib38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2002-12-3665","article-title":"\u03b3\u03b4 T cells for immune therapy of patients with lymphoid malignancies","volume":"102","author":"Wilhelm","year":"2003","journal-title":"Blood."},{"key":"2024020318425778100_bib39","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00262-011-1049-8","article-title":"Pilot trial of interleukin-2 and zoledronic acid to augment \u03b3\u03b4 T cells as treatment for patients with refractory renal cell carcinoma","volume":"60","author":"Lang","year":"2011","journal-title":"Cancer Immunol Immunother."},{"key":"2024020318425778100_bib40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2403693","article-title":"Effector \u03b3\u03b4 T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma","volume":"19","author":"Mariani","year":"2005","journal-title":"Leukemia."},{"key":"2024020318425778100_bib41","first-page":"29","article-title":"Dysfunctional V\u03b39V\u03b42 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells","author":"Coscia","year":"2012","journal-title":"Blood."}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.1797","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/3\/464\/56564170\/1797_ftp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/28\/3\/464\/56564170\/1797_ftp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T10:48:05Z","timestamp":1710326885000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/28\/3\/464-471\/7598754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,16]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2012,10,16]]},"published-print":{"date-parts":[[2013,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.1797","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717962294.793469723","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717962294.793465653","asserted-by":"object"}]},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,3,1]]},"published":{"date-parts":[[2012,10,16]]}}}